Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1100-1114

  Ingrassia, Laurent ^a   Lefranc, Florence ^b,e   Dewelle, Janique ^a   Pottier, Laurent ^b   Mathieu, Véronique ^b   Spiegl Kreinecker, Sabine ^c   Sauvage, Sébastien ^a   Yazidi, Mohamed El ^a   Dehoux, Mischaël ^a   Berger, Walter ^d   Van Quaquebeke, Eric ^a   Kiss, Robert ^b,e  

^a Unibioscreen SA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e FNRS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4 TRIHYDROXY 7 (3,4,5 TRIHYDROXY 6 HYDROXYMETHYLTETRAHYDRO PYRAN 2 YLOXY) 3,4,4A,5 TETRAHYDRO 2H [1,3]DIOXOLO[4,5 J]PHENANTHRIDIN 6 ONE; AMARYLLIDACEAE ISOCARBOSTYRIL DERIVATIVE; ANTINEOPLASTIC AGENT; LYCORICIDINE; NARCICLASINE; PACLITAXEL; PANCRATISTATIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG STABILITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO SELECTION; IN VIVO STUDY; MOUSE; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG ADMINISTRATION ROUTES; DRUG STABILITY; GLIOMA; HUMANS; MICE; PHENANTHRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64349093471     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8013585     Document Type: Article

References (47)

1. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 2005, 23, 2411-2422.
2. Eberle, J.; Kurbanov, B. M.; Hossini, A. M.; Trefzer, U.; Fecker, L. F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Updates 2007, 10, 218-234.
3. Malthaner, R. A.; Collin, S.; Fenlon, D. Preoperative Chemotherapy for Resectable Thoracic Esophageal cancer. Review, The Cochrane Library; John Wiley & Sons: New York, 2007; pp 1-34.
4. Giovannetti, E.; Mey, V.; Nannizzi, S.; Pasqualetti, G.; Del Tacca, M.; Danesi, R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 2006, 5, 1387-1395.
5. Uzzo, R. G.; Haas, N. B.; Crispen, P. L.; Kolenko, V. M. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer 2008, 112, 1660-1671.
6. Shivapurkar, N.; Reddy, J.; Chaudhary, P. M.; Gazdar, A. F. Apoptosis and lung cancer: a review. J. Cell Biochem. 2003, 88, 885-898.
7. Lefranc, F.; Facchini, V.; Kiss, R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007, 12, 1395-1403.
8. Lefranc, F.; James, S.; Camby, I.; Gaussin, J. F.; Darro, F.; Brotchi, J.; Gabius, H. J.; Kiss, R. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J. Neurosurg. 2005, 102, 706-714.
9. Joseph, B.; Darro, F.; Behard, A.; Lesur, B.; Collignon, F.; Decae- stecker, C.; Frydman, A.; Guillaumet, G.; Kiss, R. 3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J. Med. Chem. 2002, 45, 2543-2555.
10. Ingrassia, L.; Nshimyumukiza, P.; Dewelle, J.; Lefranc, F.; Wlodarc- zak, L.; Thomas, S.; Dielie, G.; Chiron, C.; Zedde, C.; Tisnes, P.; van Soest, R.; Braeckman, J. C.; Darro, F.; Kiss, R. A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J. Med. Chem. 2006, 49, 1800-1807.
11. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 2005, 4, 206-220.
12. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
13. Mann, J. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2002, 2, 143-148.
14. Altmann, K. H.; Gertsch, J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rev. 2007, 24, 327-357.
15. Ingrassia, L.; Lefranc, F.; Mathieu, V.; Darro, F.; Kiss, R. Amaryl- lidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Transl. Oncol. 2008, 1, 1-13.
16. Kornienko, A.; Evidente, A. Chemistry, biology, and medicinal potential of narciclasine and its congeners. Chem. Rev. 2008, 108, 1982-2014.
17. Ceriotti, G. Narciclasine: an antimitotic substance from narcissus bulbs. Nature 1967, 213, 595-596.
18. Carrasco, L.; Fresno, M.; Vazquez, D. Narciclasine: an antitumoral alkaloid which blocks peptide bound formation by eukaryotic riobo- somes. FEBS Lett. 1975, 52, 236-239.
19. MacLachlan, A.; Kekre, N.; McNulty, J.; Pandey, S. Pancratistatin: a natural anticancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 2005, 10, 619-630.
20. Dumont, P.; Ingrassia, L.; Rouzeau, S.; Ribaucour, F.; Thomas, S.; Roland, I.; Darro, F.; Lefranc, F.; Kiss, R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 2007, 9, 766-776.
21. Hayot, C.; Debeir, O.; Van Ham, P.; Van Damme, M.; Kiss, R.; Decaestecker, C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol. Appl. Pharmacol. 2006, 211, 30-40.
22. Decaestecker, C.; Debeir, O.; Van Ham, P.; Kiss, R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med. Res. Rev. 2007, 27, 149-176.
23. Kireev, A. S.; Nadein, O. N.; Agustin, V. J.; Bush, N. E.; Evidente, A.; Manpadi, M.; Ogasawara, M. A.; Rastogi, S. K.; Rogelj, S.; Shors, S. T.; Kornienko, A. Synthesis and biological evaluation of aromatic analogues of condritol F, L-chiro-inositol, and dihydroconduritol F structurally related to the Amaryllidaceae anticancer constituents. J. Org. Chem. 2006, 71, 5694-5707.
24. Nadein, O. N.; Kornienko, A. An approach to pancratistatins via ring- closing metathesis: efficient synthesis of novel 1-aryl-1-deoxycondu- ritols F. Org. Lett. 2004, 6, 831-834.
25. Ingrassia, L.; Wlodarczak, L.; Thomas, S.; Van Quaquebeke E.; Van den Hove, L.; Kiss, R.; Darro, F. New isocarbostyril alkaloid derivatives. Patent WO2008043846, 2008.
26. 13C-NMR data and a new improved method of preparation. Planta Med. 1991, 57, 293-294.
27. Pettit, G. R.; Melody, N.; Herald, D. L. Antineoplastic agents: 450. Synthesis of (+)-pancratistatin from (+)-narciclasine as relay. J. Org. Chem. 2001, 66, 2583-2587.
28. Pettit, G. R.; Orr, B.; Ducki, S. Synthesis of pancratistatin prodrugs. WIPO patent WO02085848, October 31, 2002.
29. Branle, F.; Lefranc, F.; Camby, I.; Jeuken, J.; Geurts-Moespot, A.; Sprenger, S.; Sweep, F.; Kiss, R.; Salmon, I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19 deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 2002, 95, 641-655.
30. Belot, N.; Rorive, S.; Doyen, I.; Lefranc, F.; Bruyneel, E.; Dedecker, R.; Micik, S.; Brotchi, J.; Decaestecker, C.; Salmon, I.; Kiss, R.; Camby, I. Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 2001, 36, 375-390.
31. Roos, W. P.; Batista, L. F.; Naumann, S. C.; Wick, W.; Weller, M.; Menck, C. F.; Kaina, B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Onco-gene 2007, 26, 186-197.
32. Mathieu, A.; Remmelink, M.; D'Haene, N.; Penant, S.; Gaussin, J. F.; Van Ginckel, R.; Darro, F.; Kiss, R.; Salmon, I. Development of a chemoresistant orthotopic human non-small cell lung carcinoma model in nude mice. Cancer 2004, 101, 1908-1918.
33. Mijatovic, T.; Mathieu, V.; Gaussin, J. F.; De Neve, N.; Ribaucour, F.; Van Quaquebeke, E.; Dumont, P.; Darro, F.; Kiss, R. Cardenolide- induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006, 8, 402-412.
34. Mijatovic, T.; Op De Beeck, A.; Van Quaquebeke, E.; Dewelle, J.; Darro, F.; de Launoit, Y.; Kiss, R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther. 2006, 5, 391-399.
35. Pettit, G. R.; Eastham, S. A.; Melody, N.; Orr, B.; Herald, D. L.; McGregor, J.; Knight, J. C.; Doubek, D. L.; Pettit III, G. R.; Garner, L. C.; Bell, J. A. Isolation and structural modification of 7-deoxynar- ciclasine and 7-deoxy-trans-dihydronarciclasine. J. Nat. Prod. 2006, 69, 7-13.
36. McNulty, J.; Mao, J.; Gibe, R.; Mo, R.; Wolf, S.; Pettit, G. R.; Herald, D. L.; Boyd, M. R. Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore. Bioorg. Med. Chem. Lett. 2001, 11, 169-172.
37. Rinner, U.; Hillebrenner, H. L.; Adams, D. R.; Hudlicky, T.; Pettit, G. R. Synthesis and biological activity of some structural modifications of pancratistatin. Bioorg. Med. Chem. Lett. 2004, 14, 2911-2915.
38. Abou-Donia, A. H.; De Guilio, A.; Evidente, A.; Gaber, M.; Habib, A.-A.; Lanzetta, R.; Seif El Din, A. Narciclasine-4-O-/3-D-glucopy- ranoside, a glucosyloxy amidic phenanthridone derivative from Pancratium maritimum. Phytochemistry 1991, 30, 3445-3448.
39. Van Quaquebeke, E.; Mahieu, T.; Dumont, P.; Dewelle, J.; Ribaucour, F.; Simon, G.; Sauvage, S.; Gaussin, J. F.; Tuti, J.; El Yazidi, M.; Van Vynckt, F.; Mijatovic, T.; Lefranc, F.; Darro, F.; Kiss, R. 2,2,2-Trichloro-N-({2-[2- (dimethylamino)ethyl]-1,3-dihydro-1H-benzo[de-]isoquinolin-5yl}carbamoyl) acetamide (UNBS3157), a novel novel-matotoxic naphthalimide derivative with potent antitumor activity. J. Med. Chem. 2007, 50, 4122-4134.
40. Le Mercier, M.; Lefranc, F.; Mijatovic, T.; Debeir, O.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Kiss, R.; Mathieu, V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol. Appl. Pharmacol. 2008, 229, 172-183.
41. Le Mercier, M.; Mathieu, V.; Haibe-Kains, B.; Bontempi, G.; Mijatovic, T.; Decaestecker, C.; Kiss, R.; Lefranc, F. Knocking down galectin-1 in human Hs683 glioblastoma cells impairs both angiogen- esis through ORP150 depletion and endoplasmic reticulum stress responses. J. Neuropathol. Exp. Neurol. 2008, 67, 456-469.
42. Berger, W.; Spiegl-Kreinecker, S.; Buchroithner, J.; Elbling, L.; Pirker, C.; Fischer, J.; Micksche, M. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int. J. Cancer 2001, 94, 377-382.
43. Griffin, C.; Sharda, N.; Sood, D.; Nair, J.; McNulty, J.; Pandey, S. Selective cytotoxicity of pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds. Cancer Cell Int. 2007, 7, 10.
44. Ghosh, M.; Song, X.; Mouneimne, G.; Sidani, M.; Lawrence, D. S.; Condeelis, J. S. Cofilin promotes actin polymerization and defines the direction of cell motility. Science 2004, 304, 743-746.
45. Yap, C. T.; Simpson, T. I.; Pratt, T.; Price, D. J.; Maciver, S. K. The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner. Cell Motil Cytoskeleton 2005, 60, 153-165.
46. Jansen, R. P. RNA-cytoskeletal associations. FASEB J. 1999, 13, 455-466.
47. Mégalizzi, V.; Mathieu, V.; Mijatovic, T.; Gailly, P.; Debeir, O.; De Neve, N.; Van Damme, M.; Bontempi, G.; Haibe-Kains, B.; Decae- stecker, C.; Kondo, Y.; Kiss, R.; Lefranc, F. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 2007, 9, 358-369.